drug
Obesity
Preclinicalupdated 6mo agoby Metallomix Inc
Preclinicalcommunity read0 votes
🐶 often sniffed alongside
top 8- tagObesity44 co-mentions · 34 sources
- tagEndocrinology & Metabolism11 co-mentions · 11 sources
- tagType 2 Diabetes8 co-mentions · 4 sources
- tagOncology3 co-mentions · 2 sources
- drugType 2 Diabetes3 co-mentions · 3 sources
- druginsulin3 co-mentions · 3 sources
- companyUniversity of Southern California2 co-mentions · 2 sources
- tagMicrobiome2 co-mentions · 2 sources
indications
indications
Obesity
all catalysts(0)
nothing on the calendar yet
Trials studying Obesity
- phase1A Phase I Clinical Study of Oral ZL-65 Tablets in Healthy and Obese Participants With Cardiovascular Risk
- N/ADASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions
- phase4Metabolic Surgery for Atrial Fibrillation Elimination
- phase1An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers.
- —DAta-driven personaLIzation of a digitAl Health Solution to Support Family Caregivers of Children With Chronic Conditions
- N/AThe Evira Study: Additional Support During Anti-Obesity Treatment
- N/AEatit's Obesity Intervention: Effects on Weight, Eating Habits and Health
- N/AMothers and CareGivers Investing in Children
News(10)
- Lilly starts work on Pennsylvania obesity plant; ITM, AtomVie strike supply dealLilly breaks ground in Pennsylvania: Eli Lilly has started construction on its $3.5 billion factory in Lehigh Valley, PA, which will manufacture obesity drugs including Lilly’s retatrutide. The sit…endpoints · 6h ago
- STAT+: Pharmalittle: We’re reading about a Merck AI deal, China and the pharma supply chain, and moreMerck is entering a research collaboration with Isomorphic Labs, the AI drug designer built on a Nobel-winning technologystat · 9h ago
- STAT+: NIH to move last group of its research chimps to a sanctuaryThe last chimpanzees owned by the U.S. government and still living in a laboratory will be moved to a sanctuary next year.stat · 1d ago
- ‘Selling and marketing snake oil’: The debate over compounded GLP-1sProponents of compounding argue it increases access, lowers prices and helps patients who may need individualized versions of a drug. But there are serious concerns, experts said at the HLTH confer…biopharma_dive · 1d ago
- Novo’s consumer push gains momentum with Wegovy pill, CagriSema on deckLAS VEGAS — When Ed Cinca returned to Novo after four years away, he barely recognized the place. “I think the building’s the same, but that’s about it,” Cinca, Novo’s senior vice president of mark…endpoints · 1d ago
- STAT+: FDA discloses reasons for rejecting Summit drugThe FDA published its complete response letter to Summit Therapeutics explaining why it rejected the biotech's closely watched lung cancer drug:stat · 1d ago
- STAT+: Pharmalittle: We’re reading about Overton FDA nomination being yanked, a Merck setback, and moreThe Trump administration is pulling the nomination of Heidi Overton to lead the FDA over concerns she lacked support to get confirmed by the Senatestat · 1d ago
- Pfizer launches into autoimmune CAR T with China's Starna in up to $2.6B dealThe Chinese biotech will work with Pfizer on three in vivo CAR T therapies for autoimmune indications.biospace · 1d ago
- Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlightThe FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech hist…biospace · 1d ago
- STAT+: Flagship opens biotech-creation outpost in the U.K.Flagship is putting up 100 million pounds to start “AI-native platform companies" focused on human and planetary health in the U.K.:stat · 2d ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that